Featured

Hello, India!

This featured post is about ChartAlert, a Real-Time-Enabled and End-of-Day Technical Analysis Advisory, Charting and Scanning Desktop Software

1–2 minutes

ChartAlert® is a Microsoft® Windows® compatible Real-Time-Enabled and End-of-Day Technical Analysis Advisory, Charting and Scanning Desktop Software that complements your trading and investing needs.

ChartAlert features three seamless modules.

1. The Charting module includes Charting and Masks.

2. The Reporting module includes Basic Advisory Content and Market Reports.

3. The Scanning module includes Basic Scanner, Advanced Scanner, RS Matrix & Trend Matrix, Trading Systems Builder and the Backtester.

Continue reading “Hello, India!”

India’s 20 years of GDP misestimation: New evidence (PIIE)

The authors — Abhishek Anand (Madras Institute of Development Studies), Josh Felman (JH Consulting) and Arvind Subramanian (Peterson Institute for International Economics) — imply India’s post-2011 GDP growth was structurally overstated by ~1.5–2.0% due to deflator and informal-sector mismeasurement, forcing investors to haircut cyclical exposures, reassess consumption-driven bets, and price in policy recalibration risks.

1–2 minutes

Based on the paper “India’s 20 years of GDP misestimation: New evidence” by authors Abhishek Anand (Madras Institute of Development Studies), Josh Felman (JH Consulting) and Arvind Subramanian (Peterson Institute for International Economics).

 The authors — Abhishek Anand (Madras Institute of Development Studies), Josh Felman (JH Consulting) and Arvind Subramanian (Peterson Institute for International Economics) — imply India’s post-2011 GDP growth was structurally overstated by ~1.5–2.0% due to deflator and informal-sector mismeasurement, forcing investors to haircut cyclical exposures, reassess consumption-driven bets, and price in policy recalibration risks.

Continue reading “India’s 20 years of GDP misestimation: New evidence (PIIE)”

MUTHOOTFIN – Q3 FY26 Earnings Call – 12-Feb-26

MUTHOOTFIN: Gold loan structural tailwinds and regulatory support underpin 18–22% AUM growth, but earnings quality hinges on NPA recovery sustainability and opex discipline; margins face 50–100 bps compression if cost inflation outpaces revenue, while competitive and macro risks cap upside to low-teens EPS growth.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: Gold prices stable (±5%), MCLR pass-through in H2, regulated branch growth.
Outcome: AUM grows 18–22%, NIM stable at ~7.5% (recoveries offset funding lag). Opex growth moderates to 15%, margins 26–28%. EPS grows 8–12%, driven by gold loan dominance and subsidiary turnarounds. Guidance clarity supports valuation rerating.

Continue reading “MUTHOOTFIN – Q3 FY26 Earnings Call – 12-Feb-26”

ZYDUSLIFE – Q3 FY26 Earnings Call – 10-Feb-26

ZYDUSLIFE’s topline: 12–15% CAGR driven by US specialty, India chronic portfolio, and International Markets; Bottomline: 8–10% EPS growth contingent on margin stability and R&D efficiency; Margins: 23–25% EBITDA range, with upside from biosimilar scaling and downside from acquisition dilution.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

  • Key Variables: Mirabegron settlement; CDMO revenue ramp-up in H2 FY27; biosimilar launches on schedule.
  • Outcome: US revenue grows 8–10% YoY, driven by specialty and generics volume. EBITDA margins stabilize at 23–25%. India and International Markets sustain 15–20% growth. Net debt reduces to ₹2,500Cr by FY28 as cash flows improve. GLP-1 captures 10–15% market share in India.
Continue reading “ZYDUSLIFE – Q3 FY26 Earnings Call – 10-Feb-26”

DIVISLAB – Q3 FY26 Earnings Call – 11-Feb-26

DIVISLAB’s growth relies on CS (57% mix), with generics resilient but pressured by pricing. Bottomline depends on CS commercialization (CY27) and cost pass-through, while margins face labor/raw material volatility, partly offset by backward integration and automation over 2–3 years.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: (1) 2/3 CS projects commercialize in Q3–Q4 CY27; (2) Generic pricing stabilizes (China’s rebate removal lifts API prices by 3–5%). Outcome: Revenue 8–10% CAGR, EBITDA margins expand 50 bps (CS mix shift), and gross asset turnover improves to 1.4x by FY28. EPS grows 8–12% annually.

Continue reading “DIVISLAB – Q3 FY26 Earnings Call – 11-Feb-26”

MAZDOCK – Q3 FY26 Earnings Call – 10-Feb-26

MAZDOCK’s topline: Structural defense tailwinds and order book visibility support 8–12% revenue CAGR, but execution risks cap upside; bottomline: EBITDA margins likely range-bound at 16–18% barring supply chain shocks; dividends: Sustainable at current payout ratios but vulnerable to capex trade-offs for next-gen projects.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: (1) P17A/MPV deliveries on schedule; (2) MOD budget grows at 8–10% annually.
Outcome: Revenue CAGR of 8–10%, margins stable at 16–18%. Dividend growth tracks earnings (₹8–10/share annually). FX neutrality assumed.

Continue reading “MAZDOCK – Q3 FY26 Earnings Call – 10-Feb-26”

INDHOTEL – Q3 FY26 Earnings Call – 12-Feb-26

INDHOTEL: Findings imply sustained double-digit topline growth (12%–14%) with EBITDA margins at 39%–40% and PAT expansion (15%–18%), contingent on RevPAR resilience, acquisition execution, and capex discipline—structural diversification and asset-light scaling remain key differentiators.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

  • RevPAR Resilience: 8.5%–10% domestic RevPAR + 12%–14% consolidated revenue growth (60+ openings, F&B/spa upside). Taj Bandstand on track for ₹1,000 crore stabilization.
  • Acquisition Synergies: Ginger reaches 250+ hotels; Atmantan/Brij contribute ₹250–300 crore. EBITDA margin sustains at 39%–40%.
  • Implication: Double-digit PAT growth (15%–18%), management fee income grows high-teens, and capital-light model drives ROIC expansion.
Continue reading “INDHOTEL – Q3 FY26 Earnings Call – 12-Feb-26”

VBL (Varun Beverages) – Q3 FY26 Earnings Call – 3-Feb-26

VBL’s topline hinges on weather normalization and Twizza execution, with 10–15% growth probable; bottomline leverages operating scale and cost absorption, targeting 12–20% EPS upside; margins face cyclical realization pressure but structural backward integration supports 23–26% India EBITDA and 17–20% ex-India EBITDA by 2027.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

  • Key Variables: Normal weather, Twizza synergies on track, snacks scale to ₹500cr.
  • Outcome: Volumes grow 10–12%; realization improves 2–3% on mix. India EBITDA margins sustain at 24–25%; ex-India margins expand to 17–18%. Free cash flow funds Twizza and brewery; dividend hike likely. Topline: +10–12%; Bottomline: +12–15%.
Continue reading “VBL (Varun Beverages) – Q3 FY26 Earnings Call – 3-Feb-26”

MOTHERSON – Q3 FY26 Earnings Call – 10-Feb-26

Motherson FY27 outlook: Revenue growth (8–15%) depends on Greenfield execution and European OEM strength; consumer electronics/aerospace scalability is pivotal. EBITDA margins may swing 50–200 bps from commodity/FX, but efficiencies and ROCE discipline cushion downside. Non-auto expansion (40%+ ROCE) offsets auto cyclicality if execution succeeds.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: (1) European OEMs stabilize market share; (2) Greenfields contribute 70% of targeted FY27 revenue; (3) consumer electronics/aerospace scale to 20M units/year by FY28.
Outcome: Revenue grows 10–12% YoY in FY27; EBITDA margins expand 50–100 bps on operational efficiencies and FX tailwinds. Leverage remains 1.0–1.2x; ROCE in new ventures hits 35–40%. Implication: Sustainable topline growth; margin expansion offsets cyclical pressures.

Continue reading “MOTHERSON – Q3 FY26 Earnings Call – 10-Feb-26”

BRITANNIA – Q3 FY26 Earnings Call – 11-Feb-26

BRITANNIA’s revenue may rise 8–10%, driven by e-commerce and adjacencies, though GST shifts and regional rivals weigh near term. Profit growth depends on commodity stability and margin discipline, with EBITDA at 19–21% if brand spend is balanced; gross margins volatile at 40–44%.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: (1) GST transition completes by Q1 FY27, (2) Commodity stability (flour/RPO ±5%).
Outcome: Revenue growth stabilizes at 8–10% (volume +5%, GST tailwinds +3–4%). Gross margins sustain at 42–44%; EBITDA margins hold at 19–21% with disciplined brand spend. Adjacencies grow at 20%+ (e-comm penetration reaches 12% by FY27). Cheese shows early turnaround signs; state incentives partially offset. Labor Code costs contained.

Continue reading “BRITANNIA – Q3 FY26 Earnings Call – 11-Feb-26”

GRASIM – Q3 FY26 Earnings Call – 11-Feb-26

Topline likely to sustain 20%+ YoY growth led by paints/B2B, but bottomline hinges on B2B breakeven timing and margin expansion in chemicals/renewables; structural premiumization in paints offsets cyclical chemical pressures, while CAPEX completion unlocks free cash flow from FY27.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

  • Key Variables: Paints price hike sticks (elasticity ~0.8x), B2B hits FY27 breakeven, chemicals EBITDA stabilizes (+2% YoY).
  • Outcome: Revenue grows 20–22% YoY; EBITDA margins expand to 15–16% on operational leverage. Paints EBITDA breakeven in FY28; B2B contributes 10% of consolidated EBITDA by FY29.
Continue reading “GRASIM – Q3 FY26 Earnings Call – 11-Feb-26”